Patent SG-11201804402W-A (SG)
Title: Thermostable fgf2 polypeptide, use thereof
Inventor: DVORAK PETR
IPC: C07K14/50
Filed: 2016-10-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/089016 Al WIPO I PCT (43) International Publication Date 1 June 2017 (01.06.2017) Jiri; Boreticka 13, 62800 Brno (CZ). BOSAKOVA, Mi- chaela; Ondrouskova 856/10, 63500 Brno (CZ). (74) Agent: DVORAKOVA, Martina; Mendlovo namesti l a, 60300 Brno (CZ). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. PCT/EP2016/073567 (51) International Patent Classification: C07K 14/50 (2006.01) (21) International Application Number: (22) International Filing Date: 3 October 2016 (03.10.2016) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 15196802.1 27 November 2015 (27.11.2015) EP (71) Applicants: MASARYKOVA UNIVERZITA [CZ/CZ]; Zerotinovo nam. 9, 60177 Brno (CZ). ENANTIS S.R.O. [CZ/CZ]; Palackeho trida 1802/129, 61200 Brno (CZ). (72) Inventors: DVORAK, Petr; Komenskeho 167, 66401 Ricmanice (CZ). KREJCI, Pavel; Podoli 391, 66403 Brno-venkov (CZ). BALEK, Lukas; Nerudova 741, 74283 Klimkovice (CZ). EISELLEOVA, Livia; Dekana Scasneho 1830/5, 95131 Mocenok (SK). KONECNA, Zaneta; Prokopa Holeho 290, Rosice nad Labem, 53351 Pardubice (CZ). DVORAK, Pavel; Obla 34, 62500 Brno (CZ). BEDNAR, David; Svazna 2, 62500 Brno (CZ). BREZOVSKY, Jan; Borodinova 24, 62300 Brno (CZ). SEBESTOVA, Eva; Dlouha 1856, 66601 Tisnov (CZ). CHALOUPKOVA, Radka; Helvikovice 144, 56401 Zam- berk (CZ). STEPANKOVA, Veronika; Zlata Hora 1240, 68401 Slavkov u Brna (CZ). VANACEK, Pavel; Zamecka 1378, 68401 Slavkov u Brna (CZ). PROKOP, Zbynek; Palackeho tr. 129, 61200 Brno (CZ). DAMBORSKY, (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art 21(3)) — with amended claims (Art 19(1)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: THERMOSTABLE FGF2 POLYPEPTIDE, USE THEREOF Ala Leu Pro Glu Asp Gly 15 Lys Asp Pro Lys Trp Leu 30 Ile His Pro Asp Gly 45 His Ile Lys Leu Gln 60 Gly Val cys Ala Asn 80 Leu Ala ser Lys Cys 95 Glu ser Asn Asn Tyr 110 Tyr Val Ala Leu Lys 125 Gly Pro Gly Gln Lys 140 Arg Leu Leu Pro 10 His Phe 25 Leu Arg Pro Ile Thr Thr Pro Pro Gly Phe Phe 40 Lys ser 55 Val Met 1 Gly Tyr val Ala Gly Gly Ala 20 Lys Asn 35 Gly val Glu Glu Leu Ala Asp Glu 100 T yr r Arg Gly Gln Leu Phe Gln 65 Arg Val val Asp Phe Tyr 120 Gly Ser Asp ser Gly Glu 105 Thr ser Ala Ser 5 Phe Gly Arg Arg Met 85 Cys Ser Tyr Leu Glu Phe Lys Leu 135 Met Ala Ser cys Asp 50 Al a Tyr Thr Thr Thr 130 Il e Gly Gl U Gly 70 Lys Phe Arg Lys Pro 150 Ile Lys 75 Arg Leu 90 Arg Leu Ser Trp Lys Thr Lys ser 155 W O 20 17 /0890 16 Al Asn Arg Ala 145 FIG.1 (57) : The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% se- quence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.